Holen Sie sich die Stockscreener-App
144.30
0.34%
0.49
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$143.81
Offen:
$143.77
24-Stunden-Volumen:
9.16M
Relative Volume:
0.96
Marktkapitalisierung:
$356.01B
Einnahmen:
$65.51B
Nettoeinkommen (Verlust:
$8.93B
KGV:
40.61
EPS:
3.5532
Netto-Cashflow:
$14.12B
1W Leistung:
-3.01%
1M Leistung:
-4.84%
6M Leistung:
+19.38%
1J Leistung:
+61.21%
1-Tages-Spanne:
$142.73
$144.35
1-Wochen-Bereich:
$142.73
$150.36
52-Wochen-Spanne:
$82.01
$156.92
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
144.30 | 354.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
141.00 | 268.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-02-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-08 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-10-13 | Fortgesetzt | Citigroup | Neutral |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-08 | Herabstufung | Truist | Buy → Hold |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
| 2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Hold |
| 2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
| 2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Eingeleitet | Jefferies | Buy |
| 2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
| 2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
| 2021-12-13 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-01 | Hochstufung | Argus | Hold → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-20 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
| 2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-03 | Eingeleitet | Mizuho | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Bestätigt | Citigroup | Buy |
| 2018-10-09 | Fortgesetzt | Guggenheim | Buy |
| 2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
| 2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Merck (MRK) director receives 55.9149 stock-linked units, payable entirely in cash - Stock Titan
Merck (MRK) director receives 111.8299 stock-linked units, payable 100% in cash after service ends. - Stock Titan
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 - Business Wire
Merck reports tulisokibart results for Merck & Co. stock - AD HOC NEWS
Merck Says Investigational Skin Therapy Shows Potential - Benzinga
Merck nabs mid-stage trial win for skin disease drug (MRK:NYSE) - Seeking Alpha
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast - GlobeNewswire Inc.
A Look at Merck & Co Inc (MRK) After 0.4% Gain -- GF Value $120. - GuruFocus
Merck & Co., Inc. (NYSE:MRK) Stock Price Target Raised at Scotiabank - MarketBeat
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline - TradingView
Merck & Co (MRK) Has Billions in Revenue to Defend. Can its Pipeline Do the Job? - Yahoo Finance
What Is Driving the Latest Milestones at Merck (NYSE:MRK)? - kalkinemedia.com
Merck, Daiichi Sankyo Pull FDA Application for Lung Cancer DrugMerck & Co (NYSE:MRK) - Benzinga
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - reuters.com
Daiichi, Merck withdraw BLA for B7-H3 ADC in small-cell lung cancer - BioWorld News
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication - TradingView
Merck closes SciBrunch KRAS licence worth up to US$2.13B - Mugglehead Investment Magazine
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor - Business Wire
Merck & Co. stock trades at USD 148.74 after pipeline updates - AD HOC NEWS
B7-H3 ADC Field Opens As Merck & Co. Pulls US Filing - insights.citeline.com
Merck (NYSE:MRK) In Focus As Oncology Advances And Pipeline Readouts Lift Its Shares Toward Rare Heights - kalkinemedia.com
Merck, Daiichi pull US application for second partnered cancer therapy - reuters.com
Here’s How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years - Benzinga
Merck, Daiichi withdraw ifinatamab FDA application - Mugglehead Investment Magazine
Merck & Co. stock is last at USD 147.97, down 0.01 percent in New York trading - AD HOC NEWS
Merck stock climbs 2.0 percent ahead of the open - AD HOC NEWS
Moderna Stock Trends After HoursModerna (NASDAQ:MRNA), Merck & Co (NYSE:MRK) - Benzinga
Alpha Buying: Follow the Money From NVIDIA and Merck - Benzinga
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine - Benzinga
What Is Driving the Latest Milestones at Merck & Co. (NYSE:MRK)? - Kalkine Media
Merck's drug for diabetes-related eye disease meets trial goal - reuters.com
Merck says remigromig met BRUNELLO vision endpoint, flags eye risks - Mugglehead Investment Magazine
Merck & Co. stock falls 1.86 percent as Q2 sales rise - AD HOC NEWS
Merck's experimental eye drug met its vision goal, but eye bleeding rates were higher than with the other drug - Stock Titan
Envestnet Portfolio Solutions Inc. Has $13.56 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Envestnet Asset Management Inc. Has $513.60 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck and Co. stock falls 1.9 percent before the bell - AD HOC NEWS
QRG Capital Management Inc. Lowers Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck (MRK) Declines More Than Market: Some Information for Investors - Yahoo Finance
Merck stock falls 2.63 percent at the close - AD HOC NEWS
Merck pipeline seen driving potential re-rating as clinical catalysts approach - Proactive financial news
Merck & Co. stock gains as Japan clears Keytruda injection - AD HOC NEWS
Merck and Co. stock gains 0.94 percent ahead of the open - AD HOC NEWS
Merck stock gains 1.97 percent at the close - AD HOC NEWS
State Street Corp Has $15.57 Billion Position in Merck & Co., Inc. $MRK - MarketBeat
MRK|Merck & Co Inc|Price:150.910|Chg%:+1.410 - TradingKey
Merck & Co. stock falls 36.58 percent year to date - AD HOC NEWS
Merck & Co., Inc. $MRK Shares Bought by Andra AP fonden - MarketBeat
Merck: Time To Trim, Overvalued, And Overbought (Rating Downgrade) (NYSE:MRK) - Seeking Alpha
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):